# World-Class DeepSynaps Medication Analyzer — 16-Week Implementation Roadmap

**Document Version**: 1.0  
**Date**: August 2025  
**Owner**: DeepSynaps Protocol Studio — Technical Product Strategy  
**Classification**: Strategic Roadmap — Engineering & Clinical Intelligence  

---

## Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [Current State Assessment](#2-current-state-assessment)
3. [16-Week Implementation Roadmap](#3-16-week-implementation-roadmap)
4. [Research Report Index](#4-research-report-index)
5. [Button / Action Matrix](#5-button--action-matrix)
6. [Key Metrics for Success](#6-key-metrics-for-success)
7. [Risk Assessment](#7-risk-assessment)
8. [Competitive Differentiation](#8-competitive-differentiation)

---

## 1. Executive Summary

The DeepSynaps Medication Analyzer is a clinician-reviewed medication decision-support workspace purpose-built for neuromodulation clinics. It provides drug-drug interaction (DDI) screening, medication-to-neuromodulation cross-checks, polypharmacy risk flags, and biomarker confound detection — all within a governance-first, audit-logged framework. This roadmap synthesizes findings from eight comprehensive research reports spanning psychiatric medication evidence (122 interactions), neuromodulation-medication interactions (12 literature-backed rules), open medication datasets (40+ projects surveyed), adverse effects matrices, biomarker confounders, nutrition/lab interactions, open-source analyzer stacks, and UX benchmarks against 20+ world-class clinical systems. The current implementation has 6 in-memory DDI rules, 12 neuromodulation-specific rules, and a functional React-based UI with patient context, timeline annotation, and review-note persistence. Over 16 weeks, this roadmap expands coverage to 25+ DDI pairs, 20+ neuromod rules, integrates RxNorm/OpenFDA for real-time data, adds pharmacogenomics panels, biomarker confound detection, nutrition/lab matrices, AI-assisted risk scoring, and delivers a world-class UX aligned with Epic, Lexicomp, and Micromedex design patterns — establishing DeepSynaps as the first medication analyzer purpose-built for neuromodulation therapy.

---

## 2. Current State Assessment

### 2.1 What Is Implemented

#### Backend (medications_router.py)
| Component | Status | Detail |
|-----------|--------|--------|
| Patient medication CRUD | Implemented | Full add/update/delete/get with SQLAlchemy persistence |
| DDI interaction checking | Implemented | 6 in-memory curated rules (sertraline+tramadol, warfarin+aspirin, SSRI+MAOI, lithium+ibuprofen, TMS+TCAs, tDCS+stimulants) |
| Interaction logging | Implemented | Full audit trail in `MedicationInteractionLog` table with JSON serialization |
| Role-based access | Implemented | `require_minimum_role(actor, "clinician")` gates all endpoints |
| Risk recompute triggers | Implemented | Auto-triggers on medication add/remove via `_trigger_med_risk_recompute` |
| FastAPI endpoints | Implemented | 5 endpoints: get meds, add med, remove med, check interactions, get log |
| Engine identification | Implemented | `ds_med_rules_v1` with transparency disclaimers |

#### Frontend (pages-medication-analyzer.js)
| Component | Status | Detail |
|-----------|--------|--------|
| Patient picker | Implemented | Dropdown patient selection with demo persona support |
| Medication list display | Implemented | Card-based medication rows with stale-record detection |
| Add medication form | Implemented | Grid-form with name, dose, frequency, route fields |
| Interaction results display | Implemented | Severity-colored cards with mechanism and recommendation |
| Neuromodulation cross-check | Implemented | Dynamic neuromod section with protocol context |
| Timeline annotation | Implemented | Save side-effect reports, missed doses, dose changes, symptom changes |
| Review notes | Implemented | Persisted clinician review notes with audit trail |
| IRB JSON export | Implemented | Full analyzer payload export for research compliance |
| Medication summary export | Implemented | JSON export of patient medication profile |
| Linked workflow navigation | Implemented | 18 linked modules (Patient profile, Assessments, qEEG, MRI, etc.) |
| Demo fixture support | Implemented | Full demo data for 3 personas with interaction examples |
| Role-based access | Implemented | `clinician`, `admin`, `clinic-admin`, `supervisor` roles |

#### Neuromodulation Rules (medication-neuromod-rules.js)
| Component | Status | Detail |
|-----------|--------|--------|
| Rule engine | Implemented | Substring-based matching with modality normalization |
| Severity tiers | Implemented | critical, major, moderate, mild, monitor |
| Reference linking | Implemented | PMID-linked references with PubMed + Evidence search buttons |
| Cross-check function | Implemented | `crossCheckMedNeuromod()` accepts meds + modalities, returns matches |

#### Medication Analyzer Service (medication_analyzer.py)
| Component | Status | Detail |
|-----------|--------|--------|
| Page payload builder | Implemented | Full `MedicationAnalyzerPagePayload` with provenance, disclosures, snapshot |
| Timeline builder | Implemented | Derives start/stop/change events from medication rows |
| Adherence estimator | Implemented | Heuristic adherence estimate (72-82% base, med-count adjusted) |
| Polypharmacy risk | Implemented | Lower/elevated/high risk bands at 5+/10+ active meds |
| Confound detection | Implemented | Mood (SSRIs), cognition (BZDs), cardiovascular (beta-blockers) domains |
| Alert generation | Implemented | DDI alerts + neuromod cautions with severity/urgency mapping |
| Recommendation engine | Implemented | Pharmacist consult, polypharmacy review, interpretation caution, adherence barrier |
| Regulatory disclosures | Implemented | Full intended use / not intended for / evidence basis / limitations |
| Audit trail | Implemented | Content-hashed audit references with SHA-256 |

### 2.2 What Is Missing (Gap Analysis)

#### Critical Gaps — Safety
| Gap | Severity | Research Basis |
|-----|----------|---------------|
| Only 6 DDI rules | Critical | Research covers 122+ documented psychiatric medication interactions |
| Only 12 neuromod rules | Critical | Research identifies 15+ additional high-priority interactions (clozapine+rTMS, anticoagulants+ECT, etc.) |
| No medication search/autocomplete | High | Manual entry risks drug name errors |
| No RxNorm normalization | High | Cannot reliably match drug variants |
| No OpenFDA adverse event lookup | High | No real-world safety signal integration |
| No severity-based alert tiers | High | All alerts presented uniformly — no tiered CDS |
| No pharmacogenomics (CPIC) | Medium | CYP2D6/CYP2C19 variants affect 30%+ of psychiatric patients |

#### Critical Gaps — Evidence
| Gap | Severity | Research Basis |
|-----|----------|---------------|
| No drug-nutrient interaction checking | High | 10+ critical interactions documented (lithium+sodium, metformin+B12, etc.) |
| No biomarker confound panel | High | 25+ medication-biomarker confound pairs documented (qEEG theta/delta + antipsychotics, BDNF + SSRIs, etc.) |
| No washout period calculator | High | Research provides specific washout periods for every medication class |
| No lab monitoring recommendations | Medium | CBC, CMP, lipid, TSH, B12, vitamin D monitoring per medication class |
| No evidence grade on alerts | Medium | Research uses A/B/C/D evidence grading throughout |

#### Critical Gaps — UX
| Gap | Severity | Research Basis |
|-----|----------|---------------|
| No medication timeline visualization | High | Timeline interfaces enable 2.2x faster medication history review |
| No network diagram for interactions | Medium | DIVA-style network views reveal interaction clusters |
| No longitudinal adherence tracking | Medium | Only point-in-time heuristic estimate exists |
| No specialty-adaptive views | Medium | Different specialties need different medication focus |
| No natural language query | Low | Micromedex-style AI search reduces lookup time |

#### Critical Gaps — Integration
| Gap | Severity | Research Basis |
|-----|----------|---------------|
| No FHIR integration | High | HAPI FHIR is de facto standard for medication interoperability |
| No RxNorm API integration | High | Gold standard for US medication terminology normalization |
| No OpenFDA API integration | Medium | Real-world adverse event data for neuromodulation patients |
| No DrugBank integration | Medium | 14,000+ drugs, 250,000+ interactions |
| No PharmGKB integration | Low | Pharmacogenomic-guided dosing annotations |

### 2.3 Critical Bugs Fixed

| # | Bug | Fix | Impact |
|---|-----|-----|--------|
| 1 | Stale medication records not flagged | Added 90-day staleness detection with amber warning banner | Prevents clinicians from relying on outdated medication data |
| 2 | Demo personas exposed real names | `DEMO_PERSONA_PUBLIC_LABEL` maps IDs to generic labels | Ensures demo data cannot be mistaken for real patients |
| 3 | Neuromod rules not re-checking on med list change | `_refreshMedListInPlace()` now re-runs `crossCheckMedNeuromod()` with updated meds | Ensures neuromod alerts stay current when medications are added/removed |

---

## 3. 16-Week Implementation Roadmap

### Phase 1 (Weeks 1-4): Safety Foundation

**Goal**: Expand rule coverage, add medication search, implement tiered alerts, and establish the safety-critical foundation for all subsequent phases.

#### Week 1: DDI Rule Expansion (6 → 25+ pairs)

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Expand `_INTERACTION_RULES` to 25+ pairs | Add high-priority psychiatric DDI pairs from Evidence Matrix | PSYCHIATRIC_MEDICATION_EVIDENCE_MATRIX.md |
| Add antipsychotic metabolic syndrome rules | Clozapine/olanzapine + diabetes risk, weight gain | MEDICATION_NUTRITION_LAB_MATRIX.md Section 1.7 |
| Add lithium-thyroid interaction rule | TSH elevation with lithium therapy | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 3 |
| Add SSRI-NSAID bleeding risk rule | Gastrointestinal bleeding risk | PSYCHIATRIC_MEDICATION_EVIDENCE_MATRIX.md |
| Add SNRI-anticoagulant interaction | Venlafaxine/duloxetine + warfarin/DOACs | MEDICATION_ADVERSE_EFFECTS_MATRIX.md |
| Unit tests for all new rules | ≥90% coverage for `_run_interaction_check()` | Engineering standard |

**Deliverables**: 25+ DDI rules with severity, mechanism, recommendation, and references for each.

#### Week 2: Neuromod Rule Expansion (12 → 20+ rules)

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Add qEEG confound rules | Antipsychotic → theta/delta increase; BZD → beta increase | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md |
| Add HRV confound rules | TCA/SNRI → HRV reduction; SSRI → mild HRV decrease | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 4 |
| Add BDNF confound rule | SSRI → BDNF elevation confounding neuromod outcomes | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md |
| Add inflammatory marker rules | SSRI → IL-6/TNF-α reduction | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md |
| Add washout period metadata | Attach minimum washout periods to each rule | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Washout table |
| Unit tests for all new rules | ≥90% coverage for `crossCheckMedNeuromod()` | Engineering standard |

**Deliverables**: 20+ neuromodulation rules covering qEEG, HRV, BDNF, inflammatory, and structural MRI confounds.

#### Week 3: Medication Search / Autocomplete + RxNorm Integration

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| RxNorm API integration | `rxnav.nlm.nih.gov` REST API for medication normalization | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md Section 4.1 |
| Medication autocomplete | Typeahead search with RxNorm-suggested drug names | UX_BENCHMARK.md Pattern 3 (Zero-Click) |
| Drug name normalization | Map entered names to RxCUI identifiers | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md |
| Generic↔brand mapping | Auto-link generic and brand name variants | RxNorm API `getAllRelatedInfo` |
| Fallback for offline mode | Cached RxNorm data for clinic deployments without internet | Engineering requirement |

**Deliverables**: Autocomplete medication entry with RxNorm normalization.

#### Week 4: Severity-Based Alert Tiers (Tier 0-4 CDS)

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Implement 5-tier alert system | Tier 0 (Passive) → Tier 4 (Hard Stop) | UX_BENCHMARK.md Pattern 1 |
| Tier assignment logic | Map interaction severity to alert tier | AHRQ Five Rights Framework |
| Override with structured justification | Require free-text + structured reason for Tier 3-4 overrides | Joint Commission standards |
| Alert de-duplication | Prevent same alert firing across multiple checks | UX_BENCHMARK.md Section 6.1 |
| Context-aware suppression | Suppress alerts when patient context makes them irrelevant | Alert fatigue research |
| Override audit logging | Log all overrides with timestamp, user, reason | 21 CFR Part 11 |

**Deliverables**: Tiered CDS system with override documentation and audit logging.

**Phase 1 Exit Criteria**:
- [ ] 25+ DDI rules with tests
- [ ] 20+ neuromod rules with tests
- [ ] Medication autocomplete functional
- [ ] Tier 0-4 alert system operational
- [ ] Test coverage ≥90%
- [ ] Safety audit pass rate 100%

---

### Phase 2 (Weeks 5-8): Evidence Integration

**Goal**: Integrate external medication datasets, add adverse event lookup, implement pharmacogenomics, and link evidence to every interaction card.

#### Week 5: OpenFDA Adverse Event Integration

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| OpenFDA API client | `api.fda.gov` drug/event endpoint integration | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md Section 4.2 |
| Adverse event lookup | Query FAERS data for medication + neuromodulation device combinations | OpenFDA documentation |
| Signal detection heuristic | Flag disproportionate adverse events (PRR > 2, chi-square > 4) | Pharmacovigilance standards |
| Caching layer | Cache OpenFDA results with 24-hour TTL | Performance requirement |
| Offline fallback | Graceful degradation when OpenFDA unavailable | Engineering requirement |

**Deliverables**: Real-time adverse event lookup for any medication in the analyzer.

#### Week 6: DrugBank + DDInter Dataset Integration

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| DrugBank SQLite integration | Local DrugBank database for 14,000+ drugs, 250,000+ interactions | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md Section 4.3 |
| DDInter dataset import | 200,000+ interaction pairs between 2,000+ drugs | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md Section 2.1 |
| Enhanced DDI checking | Fall back from curated rules → DrugBank → DDInter | Engineering design |
| Evidence grade mapping | Map external interaction data to A/B/C/D evidence grades | MEDICATION_EVIDENCE_MATRIX grading |
| Update pipeline | Monthly data refresh automation | Maintenance requirement |

**Deliverables**: 250,000+ interaction pairs available for checking with evidence grades.

#### Week 7: Pharmacogenomics Panel (CPIC Guidelines)

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| PharmGKB API integration | `pharmgkb.org` REST API for CPIC guidelines | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md Section 5.3 |
| CYP2D6 phenotype mapping | Poor/intermediate/extensive/ultrarapid metabolizer annotations | CPIC guidelines |
| CYP2C19 phenotype mapping | Clopidogrel, SSRI metabolism annotations | CPIC guidelines |
| Drug-gene interaction cards | Display CPIC-guided dosing recommendations | PharmGKB clinical annotations |
| Gene-drug pair rules | CYP2D6 + nortriptyline, CYP2C19 + escitalopram, etc. | CPIC psychiatric guidelines |
| Visual gene panel | Compact phenotype display in medication context | UX_BENCHMARK.md Pattern 8 |

**Deliverables**: Pharmacogenomics panel with CPIC-guided dosing for CYP2D6 and CYP2C19.

#### Week 8: Evidence-Linked Interaction Cards

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Enhanced interaction cards | Card header + mechanism + evidence grade + management + source | UX_BENCHMARK.md Pattern 7 |
| PMID linking on all alerts | Every interaction card links to PubMed references | MEDICATION_EVIDENCE_MATRIX references |
| Evidence grade badges | A (meta-analysis) > B (RCT) > C (cohort) > D (expert) | MEDICATION_EVIDENCE_MATRIX grading |
| Management recommendation engine | Suggest alternatives, monitoring, washout periods | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX washout table |
| C/D/X classification overlay | Lexicomp-style X=contraindicated, D=modify, C=monitor | UX_BENCHMARK.md Pattern 2 |
| Progressive disclosure | Summary always visible; detail on demand | UX_BENCHMARK.md Section 6.4 |

**Deliverables**: Every interaction card shows mechanism, evidence grade, management options, and PubMed references.

**Phase 2 Exit Criteria**:
- [ ] OpenFDA adverse event lookup functional
- [ ] DrugBank + DDInter integration with 250K+ pairs
- [ ] Pharmacogenomics panel with CPIC guidelines
- [ ] Evidence-linked interaction cards for all alerts
- [ ] Test coverage ≥90%
- [ ] All external API calls have offline fallbacks

---

### Phase 3 (Weeks 9-12): Multimodal Intelligence

**Goal**: Add biomarker confound detection, nutrition/lab matrices, qEEG/MRI medication effect overlays, and longitudinal medication timeline visualization.

#### Week 9: Biomarker Confound Detection Panel

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Biomarker confound engine | Expand `_confound_flags_for_meds()` to 15+ confound types | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md |
| qEEG confound detection | Antipsychotic → theta/delta; BZD → beta; Stimulant → TBR | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 1 |
| HRV confound detection | TCA/SNRI → HRV reduction; document NESDA finding | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 4 |
| BDNF confound detection | SSRI/Lithium → BDNF elevation (SMD 0.5-1.0) | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 3 |
| Inflammatory confound detection | SSRI → IL-6 (SMD 1.32), TNF-α (SMD 1.29) reduction | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 3 |
| Structural MRI confounds | Lithium → hippocampal volume increase; PFC thickness | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 2 |
| DMN connectivity confounds | SSRI → DMN connectivity decrease | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 2 |
| Washout period calculator | Auto-suggest washout periods based on medication list | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Washout table |

**Deliverables**: Comprehensive biomarker confound panel with 15+ confound types and washout calculator.

#### Week 10: Nutrition / Lab Interaction Matrix

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Drug-nutrient depletion detection | Flag statin→CoQ10, metformin→B12, anticonvulsant→vitamin D | MEDICATION_NUTRITION_LAB_MATRIX.md Section 1 |
| Nutrient effect on drug metabolism | Flag grapefruit→CYP3A4, St. John's Wort→CYP induction | MEDICATION_NUTRITION_LAB_MATRIX.md Section 2 |
| Lab monitoring recommendations | Auto-suggest baseline + follow-up labs per medication class | MEDICATION_NUTRITION_LAB_MATRIX.md Section 3 |
| Top 10 interaction alerts | Critical: lithium+sodium depletion, SJW+psychiatric meds, valproate+folate | MEDICATION_NUTRITION_LAB_MATRIX.md Section 5 |
| Repletion strategy suggestions | CoQ10 100-200mg, B12 1000mcg, vitamin D 2000-4000 IU | MEDICATION_NUTRITION_LAB_MATRIX.md |
| Dietary counseling prompts | Consistent sodium with lithium, avoid grapefruit with CYP3A4 substrates | MEDICATION_NUTRITION_LAB_MATRIX.md |

**Deliverables**: Nutrition/lab interaction matrix with depletion detection, monitoring schedules, and repletion strategies.

#### Week 11: qEEG / MRI Medication Effect Overlays

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| qEEG overlay visualization | Show expected medication effects on theta, alpha, beta, delta bands | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 1 |
| Medication effect charts | Band-power change estimates with direction and magnitude | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md |
| MRI structural overlay | Expected hippocampal/PFC volume changes by medication | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 2 |
| fMRI connectivity overlay | DMN connectivity changes by SSRI/stimulant status | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md Section 2 |
| Temporal alignment | Align medication start/stop dates with neuromodulation session dates | Engineering design |
| Effect size annotations | Show SMD or percent change estimates from research | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md |

**Deliverables**: qEEG/MRI medication effect overlays showing expected changes by medication class.

#### Week 12: Longitudinal Medication Timeline

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Timeline data model | Extend `build_medication_timeline()` with dose changes, gaps | UX_BENCHMARK.md Pattern 5 |
| Horizontal bar timeline | X-axis = time, Y-axis = medication, bar length = duration | UX_BENCHMARK.md Pattern 5 |
| Dose intensity visualization | Bar height/intensity encodes daily dose | UX_BENCHMARK.md Pattern 5 |
| Neuromod session overlay | Overlay TMS/tDCS/ECT sessions on same timeline | UX_BENCHMARK.md Pattern 5 |
| Adherence event markers | Missed doses, late doses from timeline annotations | Engineering design |
| Temporal correlation view | Align biomarker changes with medication changes | MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md |
| Export to research formats | Export timeline for IRB, publications, regulatory submissions | IRB requirement |

**Deliverables**: Interactive longitudinal medication timeline with neuromod session overlay.

**Phase 3 Exit Criteria**:
- [ ] 15+ biomarker confound types detected
- [ ] Nutrition/lab matrix with top 10 interactions
- [ ] qEEG/MRI medication effect overlays
- [ ] Longitudinal medication timeline with neuromod overlay
- [ ] Test coverage ≥90%
- [ ] All visualizations have accessible alternatives

---

### Phase 4 (Weeks 13-16): Advanced Features

**Goal**: Implement AI-assisted risk scoring, predictive adherence modeling, cross-patient cohort analysis, and regulatory compliance dashboard.

#### Week 13: AI-Assisted Interaction Risk Scoring

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Composite risk score | Weighted combination of DDI severity, neuromod risk, polypharmacy, age | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md Section 2.2 (CoMed) |
| Seizure risk calculator | Aggregate seizure threshold risk from all medications + protocol | ROSSI_2021, LEFAUCHEUR_2020 |
| Serotonin syndrome risk score | Sum serotonergic burden from all medications | PSYCHIATRIC_MEDICATION_EVIDENCE_MATRIX.md |
| Bleeding risk calculator | Combine anticoagulant, antiplatelet, SSRI, NSAID effects | MEDICATION_ADVERSE_EFFECTS_MATRIX.md |
| QT prolongation risk flag | Detect QT-prolonging medication combinations | MEDICATION_ADVERSE_EFFECTS_MATRIX.md |
| Risk score visualization | Traffic-light display with trend arrows | UX_BENCHMARK.md Pattern 8 |
| Explainable AI | Show which medications contribute most to each risk score | Transparency requirement |

**Deliverables**: Composite risk scores for seizure, serotonin syndrome, bleeding, and QT prolongation.

#### Week 14: Predictive Adherence Modeling

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Adherence prediction model | Expand heuristic to pill-burden-adjusted estimate | Literature: adherence inversely correlates with pill burden |
| Polypharmacy adherence decay | Model declining adherence with >5, >10 medications | Literature: adherence drops 10% per additional medication |
| Risk factor integration | Age, cognitive status, side effect burden, complexity score | OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md Section 2.2 |
| Adherence trend visualization | Historical adherence estimates with trend lines | UX_BENCHMARK.md Pattern 5 |
| Intervention trigger alerts | Flag patients with predicted adherence <70% for outreach | Clinical workflow |
| Deprescribing suggestions | Identify medications without clear indication for review | Beers Criteria, STOPP/START |

**Deliverables**: Predictive adherence model with trend visualization and intervention triggers.

#### Week 15: Cross-Patient Cohort Analysis

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Clinic-level medication dashboard | Aggregate medication patterns across all patients | Population health |
| Common DDI patterns | Most frequent interaction pairs in clinic cohort | Analytics |
| Neuromod protocol-medication patterns | Which medications are most common with each protocol | Clinical intelligence |
| Adverse event signal detection | Cross-patient safety signals from timeline annotations | Pharmacovigilance |
| Outcome correlation analysis | Correlate medication profiles with treatment response | Research feature |
| Cohort export for research | De-identified dataset export for IRB-approved studies | Regulatory compliance |

**Deliverables**: Clinic-level cohort dashboard with population medication intelligence.

#### Week 16: Regulatory Compliance Dashboard

| Task | Detail | Evidence Source |
|------|--------|-----------------|
| Audit trail viewer | Filterable log of all medication actions with user + timestamp | 21 CFR Part 11 |
| Override analytics | Override rates by alert type, by user, by patient | Alert fatigue research |
| Alert effectiveness metrics | Response times, appropriate action rates | Quality improvement |
| Regulatory report generator | PDF/CSV exports for Joint Commission, FDA, IRB | Compliance |
| Evidence version tracking | Track ruleset versions, evidence updates, data sources | Audit requirement |
| Access control dashboard | User role assignments, access logs, permission audits | HIPAA compliance |
| Safety event summary | Critical alerts, overrides, near-misses per reporting period | Patient safety |

**Deliverables**: Full regulatory compliance dashboard with audit viewer, override analytics, and report generation.

**Phase 4 Exit Criteria**:
- [ ] AI risk scores functional with explainability
- [ ] Predictive adherence model deployed
- [ ] Cross-patient cohort dashboard operational
- [ ] Regulatory compliance dashboard with report generation
- [ ] Test coverage ≥90%
- [ ] All features pass safety audit

---

## 4. Research Report Index

| # | Report | Summary |
|---|--------|---------|
| 1 | `PSYCHIATRIC_MEDICATION_EVIDENCE_MATRIX.md` | Documents 122 evidence-based psychiatric medication interactions across 12 drug classes (SSRIs, SNRIs, TCAs, antipsychotics, lithium, stimulants, benzodiazepines, etc.) with severity ratings, mechanism descriptions, and PubMed references. Uses A/B/C/D evidence grading. |
| 2 | `NEUROMODULATION_MEDICATION_INTERACTION_MATRIX.md` | Covers 45+ medication-neuromodulation interactions (TMS, tDCS, ECT, VNS, DBS) including seizure threshold risks, cognitive effects, and protocol modifications. Includes washout period guidelines. |
| 3 | `OPEN_MEDICATION_DATASET_STACK_REPORT.md` | Surveys 40+ open-source medication datasets and APIs including RxNorm, DrugBank, OpenFDA, ChEMBL, DailyMed, and pharmacogenomics resources. Provides integration readiness scoring. |
| 4 | `MEDICATION_ADVERSE_EFFECTS_MATRIX.md` | Maps 200+ adverse effects across 15 medication classes with frequency data, severity ratings, and temporal patterns. Includes QT prolongation, metabolic syndrome, extrapyramidal symptoms, and serotonin syndrome profiles. |
| 5 | `MEDICATION_BIOMARKER_CONFOUNDER_MATRIX.md` | Documents 25+ medication effects on clinical biomarkers (qEEG theta/delta/alpha/beta, HRV, BDNF, IL-6, TNF-α, cortisol, prolactin, TSH) with effect sizes, reversibility, and washout periods. Critical for neuromodulation outcome interpretation. |
| 6 | `MEDICATION_NUTRITION_LAB_MATRIX.md` | Covers 50+ drug-nutrient interactions (statin→CoQ10, metformin→B12, lithium→sodium, anticonvulsant→vitamin D) with repletion strategies, lab monitoring schedules, and the top 10 most clinically significant interactions. |
| 7 | `OPEN_SOURCE_MEDICATION_ANALYZER_STACK.md` | Benchmarks 40+ open-source medication analyzer projects across 7 categories (EHR platforms, DDI engines, CDS systems, APIs, pharmacology libraries) with license analysis, activity levels, and neuromodulation relevance scoring. |
| 8 | `MEDICATION_ANALYZER_UX_BENCHMARK.md` | Analyzes 20+ world-class medication management interfaces (Epic, Cerner, Lexicomp, Micromedex, UpToDate) extracting 10 actionable UX design patterns including tiered alerts, severity color progressions, card-based interactions, and longitudinal timelines. |

---

## 5. Button / Action Matrix

| UI Element | Clinical Purpose | Safety Gate | Evidence Basis |
|------------|-----------------|-------------|----------------|
| **Run interaction rule screen** | Execute pairwise DDI check against all rule databases | Requires ≥2 medications; clinician role required; all results flagged "requires review" | `_INTERACTION_RULES` (curated literature) + DrugBank + DDInter |
| **Add medication row** | Add medication to workspace list for screening | Name field required; not an e-prescription; disclaimer that it doesn't send to pharmacy | Clinician-entered data; RxNorm autocomplete validation |
| **Remove** | Remove medication from workspace list | Confirmation not required (non-destructive to prescriptions); logs action in audit trail | PatientMedication table; audit log |
| **Recompute risk categories** | Trigger medication_interaction, seizure_risk, and allergy category recomputation | Clinician role required; may take several seconds; shows loading state | `recompute_categories()` service |
| **Export medication summary (JSON)** | Export full patient medication profile for external review/research | Patient context required; includes demo flag if applicable; PHI handling disclaimer | Full payload: meds, interactions, neuromod state, risk profile, analyzer payload |
| **Export IRB JSON** | Export regulatory-compliant dataset for IRB submissions | Patient context required; includes regulatory disclosures, provenance, audit ref | `build_page_payload()` with `REGULATORY_DISCLOSURES` |
| **Save review note** | Persist clinician documentation note for chart review/handoff | Note text required; linked to patient and timestamp; not a prescription | SQLite persistence; linked to `MedicationAnalyzerReviewNote` table |
| **Add timeline annotation** | Record medication-related event (side effect, missed dose, dose change, symptom change) | Event type + timestamp required; auto-populates timestamp if empty | `MedicationAnalyzerTimelineEvent` table; structured event types |
| **Evidence search** | Search PubMed reference in local evidence corpus | No gate; opens evidence library with prefill from PMID | MEDICATION_EVIDENCE_MATRIX research corpus |
| **PubMed link** | Open PMID on PubMed in new tab | No gate; external link with noopener noreferrer | `pubmed.ncbi.nlm.nih.gov` |
| **Refresh analyzer payload** | Reload full analyzer payload from server | No gate; may update risk categories and recommendations | `build_page_payload()` service |
| **Refresh log** | Reload clinic-wide interaction check log | Clinician role required; filters to own checks unless admin | `MedicationInteractionLog` table |
| **Export log snapshot** | Download interaction log as JSON | Requires log data present; includes export timestamp | `InteractionLogOut` schema |
| **Open patient** | Select patient for medication analysis | Patient must exist in system; role-based patient access | `listPatients()` API |
| **Patient profile** | Navigate to patient profile with context | Patient context passed via `window._profilePatientId` | Linked module navigation |
| **qEEG / MRI / Voice / Video** | Navigate to biomarker modules with patient context | Patient context maintained; confound alerts cross-referenced | Linked module navigation |
| **Protocol Studio** | Navigate to protocol configuration | Patient context maintained; neuromod rules cross-referenced | Linked module navigation |
| **Risk Analyzer** | Navigate to full risk stratification | Patient context maintained; medication risk categories included | Linked module navigation |
| **Live session** | Navigate to live neuromodulation session | Patient context maintained; real-time medication alerts active | Linked module navigation |

---

## 6. Key Metrics for Success

### 6.1 Interaction Rule Coverage

| Metric | Current | Week 4 | Week 8 | Week 16 | Target |
|--------|---------|--------|--------|---------|--------|
| DDI rule pairs | 6 | 25+ | 50+ | 100+ | ≥100 |
| Neuromod rules | 12 | 20+ | 25+ | 35+ | ≥35 |
| Drug classes covered | 8 | 15 | 20 | 25 | ≥25 |
| Medication classes in rules | 6 | 12 | 15 | 18 | ≥18 |

### 6.2 Evidence Integration

| Metric | Current | Week 8 | Week 16 | Target |
|--------|---------|--------|---------|--------|
| External data sources | 0 | 3 (OpenFDA, DrugBank, RxNorm) | 5 (+PharmGKB, ChEMBL) | ≥5 |
| Interaction pairs searchable | 6 | 250,000+ | 250,000+ | ≥250,000 |
| Evidence-graded alerts | 0% | 50% | 100% | 100% |
| PMID-linked alerts | ~30% | 80% | 100% | 100% |

### 6.3 Biomarker / Nutrition Coverage

| Metric | Current | Week 9 | Week 12 | Target |
|--------|---------|--------|---------|--------|
| Biomarker confound types | 3 (mood, cognition, CV) | 15+ | 20+ | ≥20 |
| Drug-nutrient interactions | 0 | 10+ | 20+ | ≥20 |
| Lab monitoring schedules | 0 | 5+ | 10+ | ≥10 |
| Washout period rules | 0 | 10+ | 15+ | ≥15 |

### 6.4 Quality Metrics

| Metric | Target | Measurement |
|--------|--------|-------------|
| Test coverage | ≥90% | pytest + jest coverage reports |
| Safety audit pass rate | 100% | Quarterly independent safety review |
| Alert override rate | <30% | Target: tiered system reduces inappropriate overrides |
| False negative rate | <5% | Validated against Lexicomp gold standard (sample) |
| API response time (p95) | <500ms | For interaction check with 10 medications |
| Offline capability | Functional | All core features work without external APIs |

### 6.5 User Experience Metrics

| Metric | Target | Measurement |
|--------|--------|-------------|
| Time to first interaction result | <5 seconds | From medication entry to results display |
| Alert comprehension (clinician testing) | >90% | Can correctly identify severity and action |
| Feature adoption (medication search) | >80% | % of medications added via autocomplete |
| Timeline usage | >50% | % of patient views that include timeline |
| Regulatory export usage | >20% | % of clinics using IRB export quarterly |

---

## 7. Risk Assessment

### 7.1 Technical Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| External API downtime (RxNorm, OpenFDA) | High | Medium | Implement aggressive caching; all features have offline fallbacks; cached DrugBank provides 250K+ interactions locally |
| Drug name normalization errors | Medium | High | RxNorm primary + fuzzy string matching fallback; manual override always available; clinician review disclaimer on all results |
| Performance degradation with large rule sets | Medium | Medium | Rule indexing by drug class; lazy loading of evidence details; database migration for rules in V2 |
| Data synchronization between frontend/backend | Medium | Medium | Optimistic UI updates with server reconciliation; real-time WebSocket updates for shared patient contexts |
| Mobile responsiveness limitations | Low | Low | Responsive card-based design; touch-friendly controls; tested on tablet form factors common in clinics |

### 7.2 Clinical Safety Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| False negative (missed interaction) | Medium | Critical | Tiered alerting with lowest threshold for patient safety; all outputs require clinician review; quarterly safety audits against gold standard |
| Alert fatigue from expanded rules | High | Medium | Tier 0-4 system with aggressive de-duplication; context-aware suppression; continuous monitoring of override rates |
| Misinterpretation of risk scores as definitive | Medium | High | All scores labeled "model-assisted, not definitive"; regulatory disclosures on every screen; override capability always available |
| Outdated evidence in rules | Medium | Medium | Monthly ruleset version updates; evidence timestamp on every alert; integration with PubMed for recency checking |
| Demo data mistaken for real patient data | Low | Critical | Generic persona labels (`Demo persona A`); persistent amber demo banner; separate demo fixture data path |

### 7.3 Regulatory Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| FDA scrutiny of clinical decision support | Low | High | Explicit "not for autonomous prescribing" disclaimers; all outputs require clinician review; 21 CFR Part 11 audit trail; not a substitute for pharmacist review |
| HIPAA violation via patient data exposure | Low | Critical | Role-based access control; audit logging of all data access; minimum necessary principle; no PHI in logs or exports without explicit consent |
| Liability from missed interaction | Medium | High | Disclaimer that system is "not a verified drug-drug interaction database"; requires clinician/pharmacist review; does not replace formulary or pharmacist review; malpractice insurance covers CDS tools |
| IRB non-compliance for research use | Low | High | Full regulatory disclosures built into every payload; IRB JSON export with provenance; audit_ref on every analysis; version-controlled rulesets |

### 7.4 Mitigation Strategies Summary

1. **Governance-first design**: Every screen has regulatory disclosures; every action has audit logging
2. **Tiered CDS**: Prevent alert fatigue while maintaining safety for critical interactions
3. **Offline capability**: Core safety features work without internet connectivity
4. **Quarterly safety audits**: Independent review of rule accuracy against clinical gold standards
5. **Evidence versioning**: All rules versioned; all alerts timestamped; all evidence graded
6. **Clinician-in-the-loop**: System supports decisions; never makes them autonomously
7. **Gradual rollout**: Phase 1 → pilot clinic; Phase 2 → expanded clinic; Phase 3 → all clinics; Phase 4 → research sites

---

## 8. Competitive Differentiation

### 8.1 What Makes DeepSynaps Unique

| Feature | DeepSynaps | Epic/Cerner | Lexicomp | Micromedex | Drug Interaction Checker Apps |
|---------|-----------|-------------|----------|-----------|------------------------------|
| **Neuromodulation-specific rules** | Native (35+ rules) | None | None | None | None |
| **Medication↔stimulation cross-check** | Native (seizure threshold, protocol modification) | None | None | None | None |
| **Biomarker confound detection** | qEEG, HRV, BDNF, inflammatory, structural MRI | None | None | None | None |
| **Washout period calculator** | Per medication class with evidence | None | None | None | None |
| **Neuromod protocol context** | Auto-detects active protocol, cross-checks medications | None | None | None | None |
| **qEEG/MRI medication overlays** | Shows expected medication effects on biomarkers | None | None | None | None |
| **Longitudinal medication timeline** | With neuromod session overlay | Basic (Epic) | None | None | None |
| **Pharmacogenomics (CPIC)** | CYP2D6, CYP2C19 with dosing guidance | Limited | Limited | Limited | Rare |
| **Evidence-grade transparency** | A/B/C/D on every alert with PMID | Variable | Excellent | Good | Rare |
| **Tiered CDS (0-4)** | Customizable for neuromod workflows | Excellent (Epic) | N/A | N/A | Rare |
| **Regulatory/IRB export** | Built-in JSON export with full provenance | Manual | Manual | Manual | None |
| **Drug-nutrient interactions** | Depletion, repletion, monitoring schedules | None | Limited | None | None |
| **Open-source architecture** | MIT-licensed, self-hostable | Proprietary | Proprietary | Proprietary | Mixed |

### 8.2 Competitive Moats

1. **First-mover advantage**: No existing tool combines medication analysis with neuromodulation therapy — this is a greenfield space
2. **Evidence depth**: 8 research reports with 200+ references provide a clinical evidence base no competitor can quickly replicate
3. **Protocol integration**: Deep integration with DeepSynaps Protocol Studio enables medication↔protocol↔biomarker↔outcome correlation analysis
4. **Multimodal context**: Medication effects on qEEG, MRI, HRV, voice, and video create a unique confound-detection capability
5. **Research-readiness**: IRB export, regulatory disclosures, and audit trails make it suitable for clinical trials from day one
6. **Open architecture**: Integration-friendly design (FHIR, CDS Hooks, REST APIs) enables embedding in existing clinical workflows

### 8.3 Market Position

DeepSynaps Medication Analyzer occupies a unique position at the intersection of **clinical pharmacology**, **neuromodulation therapy**, and **multimodal biomarker analysis**. It is not competing directly with Epic or Cerner (EHR platforms), nor with Lexicomp or Micromedex (general drug references). Instead, it creates a new category: **neuromodulation-aware medication intelligence** — purpose-built for the ~15,000 neuromodulation clinics worldwide that currently have no medication safety tool designed for their specific clinical context.

### 8.4 Future Vision (Post-16 Weeks)

Beyond this roadmap, the DeepSynaps Medication Analyzer will evolve toward:

- **Real-time EHR integration** via FHIR APIs and CDS Hooks
- **AI-powered polypharmacy optimization** using the CoMed multi-agent approach
- **Predictive outcome modeling** correlating medication profiles with neuromodulation response
- **Population pharmacology** across the DeepSynaps patient network (de-identified)
- **Regulatory-grade evidence generation** for medication-neuromodulation interactions
- **Integration with wearable devices** for continuous adherence and physiological monitoring

---

## Appendices

### Appendix A: Evidence Grading System

| Grade | Definition | Examples |
|-------|-----------|----------|
| **A** | Meta-analysis or systematic review | SSRIs → BDNF increase (SMD 0.5-1.0), TCAs → HRV reduction |
| **B** | Randomized controlled trial | SSRI → DMN connectivity decrease, stimulant → qEEG beta increase |
| **C** | Cohort or case-control study | Lithium → hippocampal volume increase, antipsychotic → PFC changes |
| **D** | Expert opinion or preclinical | Bupropion theoretical mechanisms, limited human data |

### Appendix B: Severity Classification

| Severity | Color | Action Required | Example |
|----------|-------|----------------|---------|
| **Critical** | Red | Immediate review; consider holding/modifying | Clozapine + rTMS (seizure risk) |
| **Major** | Red-Orange | Review before next session | Lithium + rTMS, Bupropion + rTMS |
| **Moderate** | Orange | Document and monitor | TCA + rTMS, AED + tDCS |
| **Mild** | Yellow | Note in session record | Stimulant + rTMS at therapeutic dose |
| **Monitor** | Blue | Standard monitoring sufficient | SSRI + rTMS |
| **None** | Green | No action required | MAOI alone + rTMS |

### Appendix C: Washout Period Quick Reference

| Medication Class | Minimum Washout | Extended (Brain Imaging) | Source |
|-----------------|-----------------|-------------------------|--------|
| Fluoxetine (SSRI) | 4-6 weeks | 6-8 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| Other SSRIs | 1-2 weeks | 2-3 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| SNRIs | 1 week | 2 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| TCAs | 2 weeks | 3-4 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| Lithium | 1-2 weeks | 2-4 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| Methylphenidate | 24-48 hours | 3-7 days | BDIOMARKER_CONFOUNDER_MATRIX |
| Benzodiazepines (short) | 1 week | 2 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| Benzodiazepines (long) | 2-4 weeks | 4-6 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| Atypical antipsychotics | 2-4 weeks | 4-6 weeks | BDIOMARKER_CONFOUNDER_MATRIX |
| Clozapine | 2 weeks | 3-4 weeks | BDIOMARKER_CONFOUNDER_MATRIX |

### Appendix D: Key References

1. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. *Clin Neurophysiol*. 2009;120(12):2008-2039. PMID: 19833552
2. Rossi S et al. Safety and recommendations for TMS use in healthy subjects and patient populations. *Clin Neurophysiol*. 2021;132(1):269-306. PMID: 33243615
3. Lefaucheur JP et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). *Clin Neurophysiol*. 2020;131(2):474-528. PMID: 31901449
4. Licht CMM et al. Depression, antidepressants, and heart rate variability: The NESDA study. *Psychological Medicine*. 2008;38(8):1129-1136. PMID analysis
5. Zhou X et al. Meta-analysis: Antidepressants and peripheral BDNF. *PLoS ONE*. 2017;12(2):e0172270.
6. Patel et al. Meta-analysis: SSRI immunomodulatory effects on IL-6, TNF-α, CRP. *Cureus*. 2024;16(7):e63852.
7. Hafeman D et al. Lithium and gray matter volume: Meta-analysis. *Bipolar Disorders*. 2012;14(5):515-525.
8. Hajek T et al. Lithium and hippocampal volume: Meta-analysis. *Psychological Medicine*. 2012;42(1):1-10.
9. AHRQ. Clinical Decision Support: The Five Rights. Agency for Healthcare Research and Quality.
10. FDA Guidance for Industry: Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions.

---

### Appendix E: Detailed Weekly Engineering Breakdown — Phase 1

| Day | Week 1 Task | Owner | Deliverable |
|-----|-------------|-------|-------------|
| 1-2 | Expand `_INTERACTION_RULES` to 25 pairs | Backend Engineer | Updated rules array with 19 new pairs |
| 2-3 | Add antipsychotic metabolic syndrome rules | Clinical Data Specialist | 3 metabolic syndrome rules |
| 3-4 | Add lithium-thyroid + lithium-NSAID rules | Clinical Data Specialist | 2 thyroid monitoring rules |
| 4-5 | Add SSRI-NSAID bleeding risk rules | Clinical Data Specialist | 2 bleeding risk rules |
| 5 | Unit tests for all 25 rules | QA Engineer | ≥90% branch coverage |

| Day | Week 2 Task | Owner | Deliverable |
|-----|-------------|-------|-------------|
| 1-2 | Add qEEG confound rules to `MED_NEUROMOD_RULES` | Frontend Engineer | 4 new qEEG confound rules |
| 2-3 | Add HRV confound rules | Frontend Engineer | 3 HRV confound rules |
| 3-4 | Add BDNF + inflammatory confound rules | Clinical Data Specialist | 3 biomarker confound rules |
| 4-5 | Add washout period metadata to all rules | Clinical Data Specialist | Washout metadata on 20+ rules |
| 5 | Unit tests for all 20 neuromod rules | QA Engineer | ≥90% branch coverage |

| Day | Week 3 Task | Owner | Deliverable |
|-----|-------------|-------|-------------|
| 1-2 | RxNorm API client implementation | Backend Engineer | `rxnorm_client.py` with caching |
| 2-3 | Medication autocomplete component | Frontend Engineer | Typeahead with RxNorm suggestions |
| 3-4 | Drug name normalization pipeline | Backend Engineer | Normalization middleware |
| 4-5 | Offline fallback for cached RxNorm data | Backend Engineer | SQLite cache with TTL |
| 5 | Integration tests for autocomplete | QA Engineer | E2E tests with mocked RxNorm |

| Day | Week 4 Task | Owner | Deliverable |
|-----|-------------|-------|-------------|
| 1-2 | Tier 0-2 alert implementation | Frontend Engineer | Passive/informational/soft alerts |
| 2-3 | Tier 3-4 interruptive alerts | Frontend Engineer | Modal alerts with override reasons |
| 3-4 | Override justification + audit logging | Backend Engineer | Override logging to `MedicationInteractionLog` |
| 4-5 | Alert de-duplication engine | Backend Engineer | Context-aware suppression logic |
| 5 | E2E tests for tiered alert system | QA Engineer | Full alert flow tests |

### Appendix F: Architecture Overview

```
┌─────────────────────────────────────────────────────────────────┐
│                    DeepSynaps Medication Analyzer                │
│                                                                  │
│  ┌──────────────┐  ┌──────────────┐  ┌──────────────────────┐   │
│  │  Frontend    │  │   Backend    │  │   External APIs      │   │
│  │  (React)     │  │  (FastAPI)   │  │  (REST/SQLite)       │   │
│  └──────┬───────┘  └──────┬───────┘  └──────────┬───────────┘   │
│         │                  │                      │               │
│  ┌──────▼───────┐  ┌──────▼───────┐  ┌──────────▼───────────┐   │
│  │ Medication   │  │ medications_ │  │ RxNorm (NLM)         │   │
│  │ Analyzer     │  │ router.py    │  │ OpenFDA              │   │
│  │ Page         │  │              │  │ DrugBank (SQLite)    │   │
│  │              │  │ medication_  │  │ DDInter (TSV)        │   │
│  │ - Patient    │  │ analyzer.py  │  │ PharmGKB             │   │
│  │   picker     │  │              │  │                      │   │
│  │ - Med list   │  │ - DDI rules  │  │                      │   │
│  │ - Interaction│  │ - Neuromod   │  │                      │   │
│  │   cards      │  │   rules      │  │                      │   │
│  │ - Timeline   │  │ - Confound   │  │                      │   │
│  │ - Review     │  │   detection  │  │                      │   │
│  │   notes      │  │ - Risk scoring│ │                      │   │
│  └──────────────┘  └──────────────┘  └──────────────────────┘   │
│                                                                  │
│  ┌──────────────────────────────────────────────────────────┐   │
│  │                  Data Layer                               │   │
│  │  - PatientMedication (PostgreSQL/SQLite)                 │   │
│  │  - MedicationInteractionLog (JSON audit trail)           │   │
│  │  - Cached drug data (SQLite local cache)                 │   │
│  └──────────────────────────────────────────────────────────┘   │
└─────────────────────────────────────────────────────────────────┘
```

### Appendix G: Testing Strategy

| Test Type | Target | Tools | Scope |
|-----------|--------|-------|-------|
| Unit tests (backend) | ≥90% coverage | pytest | All router endpoints, interaction rules, risk scoring |
| Unit tests (frontend) | ≥90% coverage | jest | All rendering functions, rule matching, severity mapping |
| Integration tests | All external APIs | pytest + httpx | RxNorm, OpenFDA, DrugBank with mocked responses |
| E2E tests | Critical user flows | Playwright | Add medication → check interactions → export summary |
| Safety audit | Quarterly | Manual + automated | Validate rules against Lexicomp sample; review override rates |
| Performance tests | p95 <500ms | k6 | 10-medication interaction check under load |
| Accessibility tests | WCAG 2.1 AA | axe-core | All interactive elements, color contrast, keyboard nav |

### Appendix H: Technology Stack

| Layer | Technology | Version | Purpose |
|-------|-----------|---------|---------|
| Frontend | React | 18+ | UI framework |
| Frontend state | Custom (vanilla JS) | — | Lightweight state management |
| Backend | FastAPI | 0.100+ | API framework |
| Database | PostgreSQL | 15+ | Primary persistence |
| ORM | SQLAlchemy | 2.0+ | Database abstraction |
| Cache | SQLite (local) + Redis (cluster) | — | Drug data caching |
| Testing (backend) | pytest | 7+ | Unit/integration tests |
| Testing (frontend) | jest | 29+ | Unit tests |
| E2E testing | Playwright | 1.40+ | Browser automation |
| API docs | OpenAPI/Swagger | 3.0 | Auto-generated API documentation |
| Deployment | Docker | 24+ | Containerization |

### Appendix I: Detailed DDI Rule Expansion Plan (Phase 1, Week 1)

| # | Drug Pair | Severity | Mechanism | Source |
|---|-----------|----------|-----------|--------|
| 1 | Sertraline + Tramadol | Severe | Additive serotonergic (serotonin syndrome) | Existing |
| 2 | Warfarin + Aspirin | Moderate | Increased bleeding risk | Existing |
| 3 | SSRI + MAOI | Severe | High-risk serotonergic combination | Existing |
| 4 | Lithium + Ibuprofen | Moderate | NSAIDs alter lithium clearance | Existing |
| 5 | TMS + Tricyclics | Mild | Lowered seizure threshold | Existing |
| 6 | tDCS + Stimulants | Mild | Altered cortical excitability | Existing |
| 7 | Fluoxetine + Tramadol | Severe | CYP2D6 inhibition + serotonergic | PSYCH_EVIDENCE |
| 8 | Venlafaxine + Warfarin | Moderate | SNRI + anticoagulant bleeding | PSYCH_EVIDENCE |
| 9 | Mirtazapine + Linezolid | Severe | MAOI activity + serotonergic | PSYCH_EVIDENCE |
| 10 | Paroxetine + Tamoxifen | Major | CYP2D6 inhibition reduces tamoxifen efficacy | PSYCH_EVIDENCE |
| 11 | Escitalopram + QT-prolonging agents | Moderate | QTc prolongation additive | ADVERSE_FX |
| 12 | Olanzapine + Metformin | Moderate | Metabolic syndrome risk | NUTRITION_LAB |
| 13 | Lithium + ACE inhibitors | Moderate | Reduced lithium clearance | PSYCH_EVIDENCE |
| 14 | Clozapine + Carbamazepine | Severe | Myelosuppression additive | PSYCH_EVIDENCE |
| 15 | Clozapine + Benzodiazepines | Major | Additive sedation, respiratory depression | PSYCH_EVIDENCE |
| 16 | Risperidone + Fluoxetine | Moderate | CYP2D6 inhibition increases risperidone levels | PSYCH_EVIDENCE |
| 17 | Quetiapine + Erythromycin | Moderate | CYP3A4 inhibition | PSYCH_EVIDENCE |
| 18 | Valproate + Aspirin | Moderate | Displacement from protein binding | PSYCH_EVIDENCE |
| 19 | Lamotrigine + Estrogen | Moderate | Reduced lamotrigine levels | PSYCH_EVIDENCE |
| 20 | Methylphenidate + SSRIs | Monitor | Serotonergic potentiation | PSYCH_EVIDENCE |
| 21 | Atomoxetine + MAOIs | Contraindicated | Serotonin syndrome risk | PSYCH_EVIDENCE |
| 22 | Bupropion + MAOIs | Contraindicated | Hypertensive crisis risk | PSYCH_EVIDENCE |
| 23 | Duloxetine + Fluvoxamine | Major | CYP1A2/CYP2D6 dual inhibition | PSYCH_EVIDENCE |
| 24 | Aripiprazole + Fluoxetine | Moderate | CYP2D6 inhibition | PSYCH_EVIDENCE |
| 25 | Lurasidone + Grapefruit | Moderate | CYP3A4 inhibition via grapefruit | NUTRITION_LAB |

### Appendix J: Rollout Strategy

| Phase | Audience | Duration | Success Criteria |
|-------|----------|----------|-----------------|
| Alpha | Internal team + 1 pilot clinic | Weeks 1-8 | Zero critical bugs; 100% rule accuracy on validation set |
| Beta | 3-5 partner clinics | Weeks 9-12 | >80% clinician satisfaction; <5% false negative rate |
| General Availability | All DeepSynaps clinics | Weeks 13-16 | >90% feature adoption; 100% safety audit pass |
| Research Release | IRB-approved sites | Post-week 16 | Published validation study; regulatory compliance confirmed |

### Appendix K: Maintenance Cadence

| Activity | Frequency | Owner |
|----------|-----------|-------|
| Ruleset version update | Monthly | Clinical Data Specialist |
| External data refresh (DrugBank, DDInter) | Monthly | Backend Engineer |
| OpenFDA cache refresh | Daily (automated) | Backend Engineer |
| Safety audit review | Quarterly | Independent Clinical Advisor |
| Evidence recency review | Quarterly | Clinical Data Specialist |
| Override rate analysis | Monthly | Product Manager |
| User feedback synthesis | Bi-weekly | UX Researcher |
| Performance monitoring | Continuous | SRE/Backend Engineer |
| Security audit | Bi-annually | Security Engineer |
| Regulatory compliance review | Annually | Compliance Officer |

---

### Appendix L: Glossary

| Term | Definition |
|------|-----------|
| **AED** | Anti-epileptic drug |
| **BDNF** | Brain-derived neurotrophic factor |
| **CDS** | Clinical decision support |
| **CPIC** | Clinical Pharmacogenetics Implementation Consortium |
| **DDI** | Drug-drug interaction |
| **DMN** | Default mode network |
| **DOAC** | Direct oral anticoagulant |
| **ECT** | Electroconvulsive therapy |
| **HRV** | Heart rate variability |
| **IL-6** | Interleukin-6 |
| **IRB** | Institutional review board |
| **MAOI** | Monoamine oxidase inhibitor |
| **PFC** | Prefrontal cortex |
| **qEEG** | Quantitative electroencephalography |
| **RCT** | Randomized controlled trial |
| **rTMS** | Repetitive transcranial magnetic stimulation |
| **SJW** | St. John's Wort |
| **SNRI** | Serotonin-norepinephrine reuptake inhibitor |
| **SMD** | Standardized mean difference |
| **SSRI** | Selective serotonin reuptake inhibitor |
| **tACS** | Transcranial alternating current stimulation |
| **TCA** | Tricyclic antidepressant |
| **tDCS** | Transcranial direct current stimulation |
| **TNF-alpha** | Tumor necrosis factor-alpha |
| **TMS** | Transcranial magnetic stimulation |
| **VNS** | Vagus nerve stimulation |

---

*Document compiled: August 2025*  
*Total research reports synthesized: 8*  
*Total projects benchmarked: 40+*  
*Total clinical systems analyzed: 20+*  
*Total sources referenced: 200+*  
*Target implementation: 16 weeks*  
*Roadmap owner: DeepSynaps Protocol Studio — Technical Product Strategy*
